A Case Report of Advanced Gallbladder Carcinoma with Paraaortic Lymph Node Metastasis with 3 Years Recurrence Free Survival after Surgery

Background: to elucidate the predictors of progression-free survival (PFS) and overall survival (OS) in high-risk endometrial cancer patients. Methods: the medical records of all consecutivewomen with high-risk endometrial cancer were reviewed. Results: among 92 high-risk endometrial cancer patients, 30 women experienced recurrence, and 21 women died. The 5-year PFS and OS probabilities were 65.3% and 75.9%, respectively. Multivariable Cox regression revealed that body mass index (hazard ratio (HR) = 1.11), paraaortic lymph node metastasis (HR = 11.11), lymphovascular space invasion (HR = 5.61), and sandwich chemoradiotherapy (HR = 0.15) were independently predictors of PFS. Body mass index (HR = 1.31), paraaortic lymph node metastasis (HR = 32.74), non-endometrioid cell type (HR = 11.31), and sandwich chemoradiotherapy (HR = 0.07) were independently predictors of OS. Among 51 women who underwent sandwich (n = 35) or concurrent (n = 16) chemoradiotherapy, the use of sandwich chemoradiotherapy were associated with better PFS (adjusted HR = 0.26, 95% CI = 0.08–0.87, p = 0.03) and OS (adjusted HR = 0.11, 95% CI = 0.02–0.71, p = 0.02) compared with concurrent chemoradiotherapy. Conclusion: compared with concurrent chemoradiotherapy, sandwich chemoradiotherapy was associated with better PFS and OS in high-risk endometrial cancer patients. In addition, high body mass index, paraaortic lymph node metastasis, and non-endometrioid cell type were also predictors of poor OS in high-risk endometrial cancer patients.

Download Full-text

Prospective assessment of the prevalence of pelvic, paraaortic and high paraaortic lymph node metastasis in endometrial cancer

Gynecologic Oncology ◽

10.1016/j.ygyno.2013.10.002 ◽

2014 ◽

Vol 132 (1) ◽

pp. 38-43 ◽

Cited By ~ 89

Author(s):

Sanjeev Kumar ◽

Karl C. Podratz ◽

Jamie N. Bakkum-Gamez ◽

Sean C. Dowdy ◽

Amy L. Weaver ◽

...

Keyword(s):

Endometrial Cancer ◽

Lymph Node ◽

Lymph Node Metastasis ◽

Paraaortic Lymph Node ◽

Node Metastasis ◽

Prospective Assessment ◽

Paraaortic Lymph Node Metastasis

Download Full-text

Fraction of LOH on chromosome 17 and 18 (LOH-ratio) predicts colorectal cancer outcome

Journal of Clinical Oncology ◽

10.1200/jco.2006.24.18_suppl.20114 ◽

2006 ◽

Vol 24 (18_suppl) ◽

pp. 20114-20114

Author(s):

T. Kanazawa ◽

T. Watanabe ◽

H. Nagawa

Keyword(s):

Colorectal Cancer ◽

Multivariate Analysis ◽

Lymph Node ◽

Lymph Node Metastasis ◽

Chromosome 17 ◽

Rank Statistic ◽

Recurrence Free Survival ◽

Free Survival ◽

Node Metastasis ◽

Predictors Of Recurrence

20114 Background: Identification of patients at high risk for recurrence remains a central issue in the treatment of colorectal cancer. Our goal was to identify predictive factors for recurrence in colorectal cancer patients. Methods: DNA from 84 colorectal cancers were analyzed for wide-ranging allelotyping. Using 27 microsatellite markers spanning every 10cM on chromosome 17 and 18, we defined the LOH-ratio as the proportion of markers which show LOH out of 27 markers. Tumors were grouped into two groups by the median value of LOH-ratio (0.19). Recurrence free survival was compared with Kaplan-Meier analysis and log rank statistic. The Cox proportional hazards regression model was used for both univariate and multivariate analysis of recurrence free survival. Results: Log rank statistic revealed that LOH-ratio, stage, lymph node metastasis significantly related to recurrence free survival. On univariate analysis, significant predictors of Recurrence free survival were LOH-ratio, lymph node metastasis, Dukes’ classification, and pathological type. On multivariate analysis, LOH-ratio (HR 3.1, p = 0.02) and lymph node metastasis (HR 5.2, p = 0.002) independently predicted for recurrence free survival. Conclusions: LOH-ratio and lymph node metastasis were the only independent predictors of recurrence free survival. Altogether with lymph node metastasis, LOH-ratio could help to improve postoperative surveillance and adjuvant therapy. No significant financial relationships to disclose.

Download Full-text